Abstract
Haploidentical (Haplo) HCT using post-transplantation cyclophosphamide (PT-Cy) has improved donor availability. However, a matched sibling donor (MSD) is still considered the optimal donor. Using the CIBMTR database, we compared outcomes after MSD HCT vs. PT-Cy-based Haplo-HCT in AML patients in CR1. Data from 1,205 adult CR1 AML patients (PT-Cy-based Haplo-HCT: 336, MSD with calcineurin inhibitor-based GVHD prophylaxis: 869) (2008-2015) were analyzed. The Haplo group included more reduced-intensity conditioning (65% vs. 30%) and bone marrow grafts (62% vs. 7%), consistent with current practice (Table 1). In univariate analysis, the Haplo group had less chronic GVHD (26 [21-31]% vs. 56 [53-60]% at 3 years, p Our results suggest similar outcomes after current standard practices of PT-Cy-based Haplo-HCT using mostly bone marrow vs. MSD HCT using mostly peripheral blood, except for less cGVHD after Haplo-HCT. Although the groups were balanced for many important variables, the tight relationship of donor type with graft source and conditioning intensity may have influenced our findings.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
